Back to CVE records
High 7.0Published Dec 23, 2025

CVE-2025-68617FluidSynth is a software synthesizer based on the SoundFont 2 specifications.

Updated under an hour ago ()

Does this affect you?

It affects fluidsynth. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

FluidSynth is a software synthesizer based on the SoundFont 2 specifications. From versions 2.5.0 to before 2.5.2, a race condition during unloading of a DLS file can trigger a heap-based use-after-free. A concurrently running thread may be pending to unload a DLS file, leading to use of freed memory, if the synthesizer is being concurrently destroyed, or samples of the (unloaded) DLS file are concurrently used to synthesize audio. This issue has been patched in version 2.5.2. The problem will not occur, when explicitly unloading a DLS file (before synth destruction), provided that at the time of unloading, no samples of the respective file are used by active voices. The problem will not occur in versions of FluidSynth that have been compiled without native DLS support.

CVSS
7.0 HIGH (v3.1, NVD)CVSS:3.1/AV:L/AC:H/PR:N/UI:R/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-416
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Analyzed
Record last updated
Jun 17, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
fluidsynth fluidsynth
fluidsynth:fluidsynth
from 2.5.0 before 2.5.2
NVD

References

  • patch
  • patch
  • exploit, issue-tracking
  • issue-tracking
  • vendor-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.